CinCor Pharma, Inc.
CINC
Updated: 24/09/2026, 15:58:24
No historical data available
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
No summaries found.
- Share price
- $29.06
- Market cap
- $1.27B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Marc M. P. de Garidel
- Employees
- 19
- IPO date
- 07/01/2022
- Beta
- 0
- Last dividend
- $0.00
- Day range
- $29.02 – $29.35
- 52-week range
- $10.53 – $43.15
- 1-day performance
- 0.00%
- 1-year performance
- 175.97%
- Current drawdown (1Y)
- -32.65%
- CIK
- 0001868734
- CUSIP
- 17240Y109
- ISIN
- US17240Y1091
- Created
- 07/12/2025, 03:18:54
- Last update
- 24/09/2026, 15:58:24
Track CinCor Pharma, Inc. with an AI analyst
See which prediction-market events move CINC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.